Form 4: Charles River Laboratories Director Acquires Equity as Part of Compensation Package

Reshema Kemps-Polanco, a Director at Charles River Laboratories International, Inc., acquired 946 restricted stock units, an additional 630 restricted stock units in lieu of director service fees, and 2,076 stock options, all priced at $134.98 per share, as part of her compensation.

Summary

• Reshema Kemps-Polanco, a Director of Charles River Laboratories International, Inc. (CRL), acquired 946 shares of Common Stock in the form of restricted stock units (RSUs) on May 21, 2025, at a price of $134.98 per share.
• An additional 630 shares of Common Stock, also in the form of restricted stock units, were granted to Ms. Kemps-Polanco on May 21, 2025, at $134.98 per share, in lieu of director service fees for the term commencing May 20, 2025.
• Ms. Kemps-Polanco also acquired 2,076 stock options (right to buy) on May 21, 2025, with an exercise price of $134.98 per share.
• Following these transactions, Ms. Kemps-Polanco beneficially owns 1,960 shares of Common Stock (after the first RSU grant), 2,590 shares of Common Stock (after the second RSU grant), and 2,076 stock options.
• The unvested restricted stock units and stock options vest/become exercisable upon the earlier of May 21, 2026, or the business day prior to the Company's next annual meeting of shareholders.
• The stock options have an expiration date of May 21, 2035.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it indicates a director's continued commitment to the company through equity compensation, aligning their interests with shareholders. This is a routine, expected event rather than a significant new development.

Positives

• The acquisition of additional equity by a director, particularly through compensation, aligns the director's interests with those of the shareholders, potentially motivating long-term value creation.
• The grant of restricted stock units in lieu of director service fees indicates a commitment to equity-based compensation, reinforcing a long-term perspective for board members.

Future Outlook

The acquired restricted stock units and stock options are subject to a vesting schedule, becoming exercisable or vested upon the earlier of May 21, 2026, or the business day prior to the Company's next annual meeting of shareholders. The stock options have a long-term expiration date of May 21, 2035.

Industry Context

This filing reflects a standard practice in corporate governance where directors receive a portion of their compensation in equity, such as restricted stock units and stock options. This approach is common across various industries, including the life sciences and pharmaceutical services sector where Charles River Laboratories operates, as it aims to align the interests of the board members with the long-term performance of the company and its shareholders.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) and stock options as part of director compensation is a widely adopted practice across public companies, including those in the biotechnology and pharmaceutical services sectors, such as LabCorp (LH) or IQVIA (IQV).
• Equity-based compensation for directors is generally considered a best practice for aligning the interests of the board with shareholders, promoting long-term strategic decision-making and company performance.
• The vesting schedule tied to a future date or the next annual meeting is typical for such grants, ensuring continued service and commitment from the director.

Corporate Governance

Related Party Transactions

• The acquisition of common stock and stock options by Reshema Kemps-Polanco, a Director of Charles River Laboratories, constitutes a related party transaction as it involves compensation from the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The equity grants align the director's financial interests with those of the shareholders, potentially leading to more shareholder-friendly decisions and long-term value creation.
• Employees: While not directly impacted, a well-governed company with aligned leadership can indirectly benefit employees through stable growth and strategic direction.

Next Steps

• The restricted stock units and stock options will vest/become exercisable upon the earlier of May 21, 2026, or the business day prior to the Company's next annual meeting of shareholders.

Key Dates

Keywords

Charles River Laboratories, CRL, SEC Form 4, Insider Transaction, Director Compensation, Restricted Stock Units, Stock Options, Equity Compensation, Corporate Governance